Table 4.
Clinicopathological features of patients based on EGFR/CD4 status.
| Characteristics | Total cases | EGFR+ | p-value | Total cases | EGFR- | p-value | ||
| CD4+ | CD4- | CD4+ | CD4- | |||||
| Number of Cases | 59 | 19 (32.2%) | 40 (67.8%) | 83 | 30 (36.14%) | 53 (63.86%) | ||
| Sex | ||||||||
| Male | 34 | 11 (57.89%) | 23 (57.5%) | 0.98 | 48 | 19 (63.33%) | 29 (54.72%) | 0.45 |
| Female | 25 | 8 (42.11%) | 17 (42.5%) | 35 | 11 (36.67%) | 24 (45.28%) | ||
| Average Age [ ± stdev]* | ||||||||
| Male | 34 | 52.27 ± 10.69 | 60.78 ± 13.35 | 48 | 59.74 ± 8.88 | 57.41 ± 10.63 | ||
| Female | 25 | 63.75 ± 23.44 | 68.59 ± 12.26 | 35 | 65 ± 24.11 | 67.71 ± 14.52 | ||
| Smoking History | ||||||||
| Active smoker | 24 | 5 (26.32%) | 19 (47.5%) | 0.03 | 34 | 10 (34.48%) | 27 (50.94%) | 0.46 |
| Never smoker | 22 | 10 (52.63%) | 12 (30%) | 28 | 12 (41.38%) | 16 (30.19%) | ||
| Quit < 10 Years | 3 | 3 (15.79%) | 0 (0%) | 9 | 3 (10.34%) | 6 (11.32%) | ||
| Quit > 10 Years | 10 | 1 (5.26%) | 9 (22.5%) | 8 | 4 (13.79%) | 4 (7.55%) | ||
| N/A | – | 1 | ||||||
| Tumor Site | ||||||||
| Alveolar | 9 | 3 (15.79%) | 6 (15%) | 0.03 | 14 | 4 (13.33%) | 10 (18.87%) | 0.04 |
| Floor of mouth | 11 | 0 (0%) | 11 (27.5%) | 21 | 3 (10%) | 18 (33.96%) | ||
| Tongue | 27 | 14 (73.68%) | 13 (32.5%) | 26 | 11 (36.67%) | 15 (28.30%) | ||
| Other | 12 | 2 (10.53%) | 10 (25%) | 22 | 12 (40%) | 10 (18.87%) | ||
| T Stage | ||||||||
| T1 | 22 | 10 (52.63%) | 12 (30%) | 0.02 | 21 | 9 (30%) | 12 (22.64%) | 0.76 |
| T2 | 16 | 7 (36.84%) | 9 (22.5%) | 24 | 8 (26.67%) | 16 (30.19%) | ||
| T3/T4 | 21 | 2 (10.53%) | 19 (47.5%) | 38 | 13 (43.33%) | 25 (47.17%) | ||
| N Stage | ||||||||
| N0 | 27 | 15 (78.94%) | 12 (30%) | 0.002 | 45 | 18 (60%) | 27 (50.94%) | 0.72 |
| N1/2a | 16 | 2 (10.53%) | 14 (35%) | 12 | 4 (13.33%) | 8 (15.09%) | ||
| N2b/2c/3 | 16 | 2 (10.53%) | 14 (35%) | 26 | 8 (26.67%) | 18 (33.96%) | ||
| Differentiation | ||||||||
| Well | 3 | 2 (11.11%) | 1 (2.56%) | 0.36 | 12 | 7 (23.33%) | 5 (9.62%) | 0.1 |
| Moderate | 38 | 12 (66.67%) | 26 (66.67%) | 50 | 14 (46.67%) | 36 (69.23%) | ||
| Poor | 16 | 4 (22.22%) | 12 (30.77%) | 20 | 9 (30%) | 11 (21.15%) | ||
| N/A | 2 | 1 | ||||||
| Perineural invasion | ||||||||
| Yes | 35 | 9 (47.37%) | 26 (65%) | 0.20 | 37 | 11 (36.67%) | 26 (49.06%) | 0.28 |
| No | 24 | 10 (52.63%) | 14 (35%) | 46 | 19 (63.33%) | 27 (50.94%) | ||
| Lymphovascular invasion | ||||||||
| Yes | 25 | 4 (21.05%) | 21 (52.5%) | 0.02 | 29 | 7 (23.33%) | 22 (41.51%) | 0.1 |
| No | 34 | 15 (78.95%) | 19 (47.5%) | 54 | 23 (76.67%) | 31 (58.49%) | ||
| Bone invasion | ||||||||
| Yes | 15 | 1 (5.26%) | 14 (35%) | 0.01 | 29 | 9 (30%) | 20 (37.74%) | 0.48 |
| No | 44 | 18 (94.74%) | 26 (65%) | 54 | 21 (70%) | 33 (62.26%) | ||
| Local recurrence | ||||||||
| Yes | 20 | 8 (42.11%) | 12 (30%) | 0.36 | 25 | 10 (33.33%) | 15 (28.30%) | 0.63 |
| No | 39 | 11 (57.89%) | 28 (70%) | 58 | 20 (66.67%) | 38 (71.70%) | ||
*Average age at diagnosis.